Is Trident Texofab overvalued or undervalued?

As of 22 August 2025, the valuation grade for Trident Texofab has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios highlight this position, with a PE Ratio of 122.14, an EV to EBITDA of 70.73, and a PEG Ratio of 5.80, all of which are significantly higher than industry norms.
In comparison to its peers, Trident Texofab's valuation metrics stand out unfavorably. For instance, Lloyds Enterprises has a PE Ratio of 39 and an EV to EBITDA of 96.38, while PTC India, deemed very attractive, has a PE Ratio of just 8.95. The stark contrast in these ratios suggests that Trident Texofab is not only overvalued but also lacks the financial metrics to justify its current price level. Additionally, the company's stock has outperformed the Sensex in various time frames, including a remarkable 426.35% return over the past year, further complicating its valuation narrative.